Rabbit blood platelet adhesion rate testing is a widely used in vitro assay for evaluating the thrombogenic potential of blood-contacting medical devices and biomaterials in line with ISO 10993-4. By quantifying the percentage of platelets that adhere to a material surface after controlled contact with fresh rabbit platelet-rich plasma, the test delivers essential data for hemocompatibility assessment and regulatory submissions. This article explains the testing principle, sample requirements, methodology, calculation formula, and typical applications of platelet adhesion rate determination.
Technical Overview
When blood comes into contact with a foreign material surface, a cascade of events begins within seconds: plasma proteins such as fibrinogen and von Willebrand factor adsorb onto the surface, followed by platelet adhesion, activation, shape change, aggregation, and ultimately thrombus formation. Platelet adhesion is therefore one of the earliest and most informative indicators of the thrombogenic potential of a biomaterial or medical device.
Rabbit blood platelet adhesion rate testing quantifies this phenomenon by measuring the reduction in platelet count after fresh rabbit blood or platelet-rich plasma (PRP) is exposed to a test material under controlled conditions. The platelet adhesion rate is calculated according to the following formula:
Platelet Adhesion Rate (%) = (P0 − P1) / P0 × 100, where P0 is the platelet count before contact and P1 is the platelet count after contact with the test material.
A lower adhesion rate generally indicates better hemocompatibility, meaning the material is less likely to trigger thrombus formation in clinical use. This assay falls under the thrombosis testing category described in ISO 10993-4 (Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood) and its Chinese national equivalent GB/T 16886.4, and it is frequently performed alongside hemolysis, coagulation, and complement activation tests as part of a complete hemocompatibility evaluation package.
Rabbit blood is commonly selected as the test medium for several practical reasons:
- Rabbits are a well-established laboratory species, and blood collection from the ear central artery is relatively simple and reproducible.
- Rabbit platelet counts and reactivity toward artificial surfaces are sufficiently robust to generate clear, quantifiable adhesion responses.
- Sufficient blood volume can be obtained from a single donor animal to run multiple test and control samples in parallel, reducing inter-donor variability.
- The use of animal blood avoids the logistical and biosafety constraints of fresh human donor blood while remaining acceptable for comparative material screening.
Testing Samples
Intravascular and Blood-Contacting Devices
Direct-contact devices intended to interface with circulating blood represent the primary category of samples submitted for this test. Typical examples include:
- Peripheral and central venous catheters, introducer sheaths, and cannulae
- Intravascular stents, stent grafts, and vascular occlusion devices
- Artificial blood vessels, vascular grafts, and patch materials
- Extracorporeal circulation components such as tubing, oxygenator membranes, and hemodialysis hollow fibers
- Blood collection bags, transfusion sets, and blood filters
Biomaterials and Surface Coatings
Material-level samples are also routinely evaluated, particularly during research and development. These include:
- Polymer films, sheets, and membranes (e.g., polyurethane, silicone, PTFE, PVC)
- Hydrophilic, antithrombotic, or heparin-infused surface coatings
- Metallic materials such as titanium alloys, cobalt-chromium alloys, and 316L stainless steel
- Hydrogels, wound dressings with blood-contact claims, and tissue-engineering scaffolds
Sample Preparation Requirements
Samples should be prepared in accordance with ISO 10993-12 principles. Key requirements include:
- Samples must be clean, dry, sterile or non-pyrogenic as intended for clinical use, and representative of the final product configuration.
- A defined and consistent surface area must be provided for each test specimen so that results can be normalized.
- Negative control materials (such as medical-grade silicone or polyethylene with known low thrombogenicity) should be tested in parallel, and a positive reference material may be included to confirm assay sensitivity.
- Sufficient replicate specimens, typically no fewer than three per group, should be submitted to support statistical comparison.
Testing Items
The core deliverables of a rabbit blood platelet adhesion rate study typically include:
- Platelet count of the rabbit blood or PRP before contact with the test material (P0)
- Platelet count after the contact incubation period (P1)
- Calculated platelet adhesion rate for each test sample and each control material
- Comparison of the test material adhesion rate against the negative control to determine relative thrombogenic potential
- Optional morphological assessment of adhered platelets by scanning electron microscopy (SEM), including classification of activation states (round, dendritic, spread, and fully spread forms)
- Optional supplementary parameters such as platelet activation markers when a broader hemocompatibility profile is required
Testing Methods
Blood Collection and Platelet-Rich Plasma Preparation
Blood is collected from healthy adult rabbits, commonly New Zealand white rabbits, via the ear central artery or cardiac puncture under appropriate anesthesia and animal welfare controls. The blood is anticoagulated, most frequently with 3.8% sodium citrate at a 9:1 blood-to-anticoagulant ratio, although heparin may be used depending on the study protocol. To prepare platelet-rich plasma, the anticoagulated blood is centrifuged at low speed, for example approximately 200 × g for 10 minutes, and the PRP supernatant is carefully collected. Platelet counts in the PRP are measured and, if necessary, adjusted to fall within the range specified by the test protocol. Testing should be completed promptly after collection, generally within a few hours, to preserve platelet viability and responsiveness.
Contact and Incubation Procedure
The test specimens are placed in direct contact with the PRP or whole blood in sterile containers. The contact is typically conducted under the following conditions:
- Incubation temperature of 37 ± 1 °C to simulate physiological conditions
- Contact duration commonly ranging from 30 minutes to 2 hours, defined by the study protocol
- Static incubation in most standard protocols, or dynamic contact using rocking or rotating platforms when flow-related adhesion behavior is of interest
- Parallel processing of negative control samples and, where applicable, a blank tube without material contact to monitor baseline platelet stability
Platelet Counting and Adhesion Rate Calculation
After the contact period, the blood or PRP is gently separated from the specimen, and the platelet count (P1) is determined using an automated hematology analyzer or a manual counting chamber according to the validated laboratory procedure. The platelet adhesion rate is then calculated with the formula (P0 − P1) / P0 × 100%. Results for replicate specimens are averaged, and the adhesion rate of the test material is compared statistically against the negative control. A test material demonstrating an adhesion rate that is not significantly higher than the negative control is generally regarded as having acceptable platelet compatibility in this assay.
Optional SEM Morphological Evaluation
For a more detailed understanding of platelet-material interactions, adhered platelets on the specimen surface can be fixed with glutaraldehyde, dehydrated through a graded ethanol series, dried by critical point drying, sputter-coated with gold, and observed under a scanning electron microscope. This evaluation reveals the number, distribution, and morphological activation state of the adhered platelets, providing complementary qualitative evidence to the quantitative adhesion rate data.
Applications
Rabbit blood platelet adhesion rate testing supports a broad range of product development and regulatory activities:
- Hemocompatibility screening of candidate materials and antithrombotic surface coatings during the research and design phase
- Comparative evaluation of competing materials, coating processes, or manufacturing batches to guide design optimization
- Regulatory submission support for blood-contacting devices, including registration dossiers that require ISO 10993-4 thrombogenicity data
- Verification of surface modification effectiveness, such as hydrophilic coatings, heparinized surfaces, and zwitterionic polymer layers
- Quality control and batch consistency assessment for products where surface thrombogenicity is a critical quality attribute
- Academic and industrial research into platelet-surface interaction mechanisms and new biomaterial platforms
FAQ
Why is rabbit blood used instead of human blood?
Rabbit blood is used because rabbits are an established laboratory species from which fresh, sufficient-volume blood can be obtained reliably and reproducibly. Rabbit platelets respond robustly to artificial surfaces, generating clear quantitative discrimination between materials. Human blood introduces donor availability, biosafety, and inter-donor variability issues, so rabbit blood is preferred for routine comparative screening, while confirmatory testing may be performed with human donor blood where justified.
Which standards govern this test?
The test supports the thrombosis assessment requirements of ISO 10993-4 and GB/T 16886.4 for interactions with medical devices and blood. Sample preparation generally follows ISO 10993-12. Because ISO 10993-4 does not prescribe a single mandatory method, the platelet adhesion rate assay is performed according to a documented, laboratory-validated protocol with appropriate negative controls.
What result is considered acceptable?
There is no absolute pass-fail threshold defined in the standards; acceptance is judged relative to a negative control material. In general, a test material whose platelet adhesion rate is comparable to or lower than that of the negative control, with no significant increase and without extensive platelet spreading or aggregation in morphological evaluation, is considered to have acceptable platelet compatibility.
What anticoagulant is used?
Sodium citrate at a 9:1 blood-to-anticoagulant ratio is the most common choice because it preserves platelet function by chelating calcium without directly activating platelets. Heparin may be used in certain protocols, but the anticoagulant must be selected and validated so that it does not interfere with the adhesion measurement.
How should samples be submitted?
Samples should be clean, representative of the final product, and sterilized in the same manner intended for clinical use. Each group should include at least three replicate specimens with a defined contact surface area, and a negative control material should be tested alongside. Detailed sample information, including material composition, surface treatment, and intended use, helps ensure a scientifically sound study design.
Can this test be combined with other hemocompatibility tests?
Yes. Platelet adhesion rate testing is frequently performed together with hemolysis testing, coagulation assays such as PT, APTT, and TT, thrombus formation assays, and complement activation tests to build a complete ISO 10993-4 hemocompatibility profile for blood-contacting devices.